PDS Biotech gets Nasdaq notice after shares trade below $1 bid-price minimum

• PDS Biotechnology received a Nasdaq notice for failing the $1 minimum bid price rule, with shares below $1 for 30 straight sessions.
• The stock remains listed on the Nasdaq Capital Market under PDSB while the company works to regain compliance.
• Nasdaq set a 180-day cure period through Jan. 26, 2027; compliance requires a $1+ closing bid for at least 10 consecutive sessions.
• Failure to cure by the deadline could trigger delisting; the company may consider a reverse stock split to address the deficiency.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PDS Biotechnology Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-030497), on July 31, 2026, and is solely responsible for the information contained therein.